AlphaMark Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

AlphaMark Advisors’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-180	Closed	-$8K	–	531
2017 Q2	$8K	Hold	180	–	–	﹤0.01%	371
2017 Q1	$8K	Hold	180	–	–	﹤0.01%	355
2016 Q4	$7K	Buy	+180	New	+$7.27K	﹤0.01%	346

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

AlphaMark Advisors's PBE Position: Q3 2017 in Review

AlphaMark Advisors sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2017, closing a stake of 180 shares — an estimated $8K sold.

AlphaMark Advisors first reported a position in PBE in Q4 2016 and held it in 3 quarters. The position peaked at $8K in Q2 2017. 60 funds tracked by Wall St. Rank hold PBE as of Q3 2017.

AlphaMark Advisors reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2017 after selling out during the quarter.
AlphaMark Advisors sold 180 Invesco Biotechnology & Genome ETF shares in Q3 2017, an estimated $8K.
AlphaMark Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q4 2016 and held it in 3 quarters.
AlphaMark Advisors's Invesco Biotechnology & Genome ETF position peaked at $8K in Q2 2017.
60 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2017.

Based on AlphaMark Advisors's 13F filing for Q3 2017, filed 2 Nov 2017.